Otsuka Pharmaceutical Co., Ltd.

208 articles about Otsuka Pharmaceutical Co., Ltd.

• Medibio Enters Into An Agreement With Otsuka Pharmaceutical Development & Commercialization

  10/9/2017

• Otsuka Pharma And Mylan Announce License Agreement To Commercialize Delamanid (Deltyba) For Multidrug-Resistant Tuberculosis (MDR-TB) In High-Burden Countries

  8/24/2017

• Otsuka Pharma Release: ABILIFY MAINTENA (Aripiprazole) For Extended-Release Injectable Suspension Approved By U.S. FDA For Maintenance Monotherapy Treatment Of Bipolar I Disorder

  7/31/2017

• Otsuka Pharma Announces The Acquisition Of Rapidly Growing Plant-Based Food Innovator Daiya

  7/28/2017

• Otsuka Pharma And Proteus Digital Health Resubmit Application To FDA For First Digital Medicine

  5/23/2017

• Otsuka Pharma Announces Results Of Phase III Data On Tolvaptan

  5/22/2017

• Otsuka Pharma And Teva Sign Licensing Agreement For Japan On Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

  5/15/2017

• Otsuka Pharma Release: Launch Of Alzheimer’s Journey Coordinator Certificate Program

  5/10/2017

• Otsuka Pharma And Lundbeck Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia

  5/2/2017

• Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck, Otsuka Pharma Investors Unsettled

  5/2/2017

• Why Akebia, Even With Otsuka Pharma's Big Deal, May Need To Be Acquired

  4/27/2017

• Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal

  4/26/2017

• Otsuka Pharma Plunks Down $250 Million for Cambridge Biotech Neurovance for Late-Stage Ready ADHD Drug

  3/3/2017

• Health Canada Approves Otsuka Pharma And Lundbeck's REXULTI (Brexpiprazole) As A Treatment For Schizophrenia In Adults

  2/20/2017

• Akebia Forges $1B U.S. Deal with Otsuka Pharma on Late-Stage Drug

  12/20/2016

• Otsuka Pharma Release: FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena (Aripiprazole) For The Treatment Of Bipolar I Disorder

  11/30/2016

• Otsuka Pharma Release: ORALTAG (Iohexol), A New Oral Contrast Agent For Abdominal CT Scans, Launched In U.S.

  7/5/2016

• Amid Insider Trader Investigations, Acucela and Otsuka Pharma Kill Glaucoma Drug Deal After Failed Trial

  6/14/2016

• Otsuka Pharma Release: 48-Week Data, Presented At The Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit With Adacolumn In A Sub-Group Of Refractory Patients With Ulcerative Colitis

  5/23/2016

• FDA Spurns Otsuka Pharma, Proteus Digital Health's Drug/Device Combo

  4/27/2016